MGC Pharmaceuticals Ltd.
Compliance Filing of UK subsidiary FY21 Accounts
27 May 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), would like to advise the market on the status of the filing of its MGC Pharma UK subsidiary accounts to year end 30 June 2021 at Companies House, following the completion and lodgement of the Group's audited accounts on 30 September 2021.
Through the appointment and handover process of the Company's new CFO, there was an administrative oversight in the filing of Company's subsidiary MGC Pharma UK Ltd 2021 accounts at Companies House. This has now been recently identified by the new Chief Financial Officer as part of a compliance review for all the Group's operating entities and local compliance filings, and is now in the process of being rectified with Companies House for our UK subsidiary, which will be completed week commencing 30th May 2022.
The Company's 2021 Full Year Audited Annual Report and Accounts can be viewed on the company's website:
https://mgcpharma.eu/investor-centre/reports/
--Ends-
Authorised for release by the Managing Director, for further information please contact:
| MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390
| MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.eu
|
| UK Broker - Turner Pope Andy Thacker +44 203 657 0050
| UK PR Advisors - Tavistock Tim Pearson +44 207 920 3150
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - Epilepsy and Dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
